Abstract: . . .  sales of Diovan. In particular, management's expectations regarding commercialization of Diovan could be affected by, among other things, additional analysis of Diovan clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally; the company's . . .
. . .  john.gilardi@novartis.com 1/3 MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Diovan receives EU approval for the treatment of heart attack survivors Leading antihypertensive agent Diovan is first in its class to receive approval to  . . .
. . .  terminology such as is being evaluated or similar expressions, or by express or implied discussions regarding potential new indications or labeling and marketing approvals for Diovan or regarding potential future sales of Diovan. Such forward-looking statements involve known and unknown risks, uncertainties and other factors . . .
. . .  324 3018 (direct) +41 79 596 1408 (mobile) john.gilardi@novartis.com References 1 World Health Organization, European Health for All Database, Hospital discharges, ischemic heart disease. Available at http://hfadb.who.dk/hfa/ . 2 World Health Organization, International . . .
. . .  heart disease. Available at http://hfadb.who.dk/hfa/ . 2 World Health Organization, International Classification of Diseases, Diseases of the Circulatory System. 3 American Heart Association, Heart Disease and Stroke Statistics 2004 Update. 4 National, Heart , Lung . . .
. . .  also take usual therapy including diuretics, digitalis and either beta blockers or ACE inhibitors, but not both. This new indication for Diovan is for the treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent myocardial infarction . . .
--1999,6,167,2481,9997